Know Labs today said it entered a research agreement with the Mayo Clinic to test and validate its Bio-RFID as a continuous glucose monitor.
Know Labs’ Bio-RFID technology is designed to be integrated in a number of wearable, mobile or bench-top form factors.
“We are very pleased to work with Mayo Clinic. They bring a world-renowned reputation in diagnostics. We look forward to working with them during this research project as we continue the development of our non-invasive UBand CGM,” Know Labs CEO Phil Bosua said in a news release.
Know Labs plans to launch its Bio-RFID within its wearable UBand as a non-invasive continuous glucose monitor.